Our Investors

Ampersand Ventures

Founded in 1988, Ampersand is a leading private equity investment firm with offices in Wellesley, MA and San Diego, CA. Ampersand currently manages $550 million in committed capital with investments targeted in the life sciences, information technology, and specialty materials and chemicals sectors. For more information visit: http://www.ampersandventures.com/

Gold Hill Capital

Gold Hill Capital is an independent, private financing firm focused on providing capital to successful companies within the technology and life science industries. Gold Hill is capitalized by top-tier institutional investors with aggregate investment capital of approximately $1 billion deployed over two funds.

Gold Hill has a highly-focused team dedicated to delivering flexible financing solutions for expansion stage companies. Our team provides an unparalleled level of financial experience working with technology companies experience that includes investment banking, venture capital, international finance, mezzanine finance and asset-based lending. Gold Hill is headquartered in San Jose, CA with an office in Boston, MA. For more information visit: http://www.goldhillcapital.com

Nexus Medical Partners

The Nexus Group is a private equity firm managing several funds with offices in Massachusetts and South Carolina and affiliates in San Francisco, London, Munich, Geneva and Tokyo. The Group specializes in making private equity investments and in providing strategic assistance to medical technology and life science companies globally. For more information visit: http://www.nexusmp.com/

Novartis Option Fund

The Novartis Option Fund is a $200 million fund that is part of the Novartis Corporate Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over $550 million in committed capital and is invested in more than 50 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow-on investment. The Novartis Venture Funds team of nine investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital. For more information, visit http://www.venturefund.novartis.com

Pappas Ventures

Pappas Ventures is a Research Triangle Park, North Carolina-based venture capital firm that invests nationally in the life science industry. Founded in 1994, Pappas has $250 million under management. The firm’s primary investment focus is on product oriented biotechnology and pharmaceutical companies with a secondary focus on medical technologies. For more information visit: http://www.pappasventures.com/

Yasuda Enterprise Development

Yasuda Enterprise Development Co., Ltd., is one of the largest and most experienced venture capital firms in Japan. With more than $900 million currently under management, Yasuda has supported more than 200 IPOs since its inception. Yasuda has built strong networks with pharmaceutical industries in Japan as well as investor bases in Asia and provides international business development as well as syndication support to its portfolio companies. For more information visit: http://www.yedvc.co.jp/